Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2512233 | 0.85 | TNK2 (0.53) | TNK2PDE10ABTK | |
| SCHEMBL3342007 | 0.81 | — | — | |
| SCHEMBL3340946 | 0.75 | PDE10A (0.64) | PDE10A | |
| SCHEMBL4014684 | 0.74 | PDE10A (0.56) | PDE10AALDH1A1SMN1; SMN2BTK | |
| SCHEMBL27911596 | 0.74 | ALDH1A1 (0.49) | TNK2ALDH1A1SMN1; SMN2TRPV1 | |
| SCHEMBL27762102 | 0.74 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL4008464 | 0.73 | PDE10A (0.51) | PDE10AALDH1A1SMN1; SMN2TRPV1 | |
| SCHEMBL23235670 | 0.72 | ALDH1A1 (0.43) | TNK2PDE10AALDH1A1SMN1; SMN2TRPV1 | |
| SCHEMBL3344262 | 0.72 | PDE10A (0.57) | PDE10A | |
| SCHEMBL2486508 | 0.71 | PDE10A (0.41) | PDE10AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637500-B2 | Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2014-01-28 | — | — | US | disclosed |
| EP-2376455-B1 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC (US) | 2012-11-14 | — | — | EP | disclosed |
| US-20100160280-A1 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160280-A1 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | PDE4A, PDE7A, PDE4D | TNK2 1871/4885PDE10A 10/4885ALDH1A1 1600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.